Vietnam's Vaccine Market Expands as Domestic Manufacturing and Life-Course Immunisation Drive Growth

Vietnam is rapidly strengthening its vaccine ecosystem, combining one of Southeast Asia's most comprehensive immunisation programmes with increasing domestic manufacturing capability and growing investment in biotechnology. As governments and healthcare providers shift their focus beyond childhood immunisation towards life-course vaccination and pandemic preparedness, the country's vaccine market is entering a new phase of sustained growth.

According to IMARC Group, Vietnam's Vaccine Market was valued at US$904.5 million in 2025 and is forecast to reach US$1.52 billion by 2034. Market expansion is being supported by increasing public awareness of preventive healthcare, rising vaccination coverage, technological advances in vaccine development and growing demand across both public and private healthcare sectors.

Vaccines remain one of the most effective public health interventions, protecting populations against infectious diseases while reducing long-term healthcare costs. Vietnam has built a strong immunisation infrastructure through its Expanded Programme on Immunization (EPI), which has significantly reduced the incidence of vaccine-preventable diseases over recent decades. Today, vaccination demand extends well beyond childhood immunisation to include adolescent, adult and elderly populations, creating new commercial opportunities across the healthcare sector.

The market encompasses a broad range of vaccine technologies and applications, including:

• Routine childhood immunisation
• Influenza vaccines
• Human papillomavirus (HPV) vaccines
• Pneumococcal vaccines
• Combination vaccines
• COVID-19 vaccines
• Recombinant vaccines
• mRNA vaccines
• Travel vaccines
• Therapeutic vaccines under development

One of the most significant developments in Vietnam's pharmaceutical industry is the expansion of domestic vaccine manufacturing. In 2025, Sanofi and Vietnam Vaccine JSC (VNVC) inaugurated a new vaccine manufacturing facility in Long An Province with an initial investment of approximately US$77 million. Designed to produce up to 100 million doses annually, the facility is expected to begin operations by the end of 2027 and will serve both domestic and export markets. Alongside the investment, the companies signed a technology transfer agreement, further strengthening Vietnam's long-term vaccine manufacturing capability.

Domestic production has become a strategic priority as governments worldwide seek to improve vaccine security following the COVID-19 pandemic. Vietnam is increasingly investing in local manufacturing capacity, cold-chain infrastructure and biotechnology research to reduce dependence on imported vaccines while improving preparedness for future public health emergencies.

The country's growing emphasis on life-course immunisation is also reshaping demand. While childhood vaccination remains the cornerstone of national immunisation policy, increasing attention is being given to protecting adolescents, adults and older populations against diseases such as influenza, pneumococcal infections, shingles and HPV. As Vietnam's population ages and non-communicable diseases become more prevalent, preventive vaccination is expected to play an increasingly important role in reducing healthcare costs and improving healthy ageing.

Innovation continues to transform vaccine development globally. Advances in mRNA technology, recombinant vaccines, viral vectors and adjuvant platforms are shortening development timelines while improving efficacy against both existing and emerging infectious diseases. Artificial intelligence, genomics and digital manufacturing technologies are also accelerating vaccine discovery and production, enabling more rapid responses to future outbreaks.

The global vaccine industry continues to expand as governments strengthen pandemic preparedness and invest in routine immunisation. According to the World Health Organization, vaccines remain among the most cost-effective public health interventions, while continued innovation is expanding the pipeline for infectious diseases, cancer immunotherapy and personalised medicine.

Leading companies operating in the global vaccine market include GSK, Sanofi, Pfizer, Moderna, Merck & Co. (MSD), AstraZeneca, CSL Seqirus, Bharat Biotech, Serum Institute of India, BioNTech and Sinovac. These organisations continue to invest heavily in next-generation vaccine technologies, manufacturing capacity and global distribution networks.

Vietnam's combination of a mature immunisation programme, supportive government policy, expanding domestic manufacturing and increasing biotechnology investment positions it as one of Southeast Asia's most attractive vaccine markets. For vaccine manufacturers, biotechnology companies, cold-chain providers, pharmaceutical equipment suppliers, contract manufacturers and clinical research organisations, the country offers substantial long-term opportunities as demand for preventive healthcare continues to grow.

READ THE FULL INSIGHTS REPORT